Showing results (261-270 of 405) with videos related to
Sort By:
Pageof 41
The Journal of Experimental Medicine|July 9, 2003
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) miceMohammed Javeed I Ansari, Alan D Salama, Tanuja Chitnis, et al.Annals of Neurology|April 16, 2022
Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple SclerosisGauruv Bose, Brian C Healy, Hrishikesh A Lokhande, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 8, 2025
A multicenter cohort of transgender and gender diverse people with multiple sclerosisAlexandra Balshi, Talia B Feldman, John P Dempsey, et al.Pediatric Neurology|December 28, 2023
Assessing Needs and Perceptions of Research Participation in Pediatric-Onset Multiple Sclerosis: A Multistakeholder SurveyClaudia Gambrah-Lyles, Varun Kannan, Tim Lotze, et al.Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare SystemsZiming Gan, Wen Zhu, Weijing Tang, et al.The Lancet. Neurology|November 20, 2021
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trialTanuja Chitnis, Brenda Banwell, Ludwig Kappos, et al.Archives of Neurology|December 15, 2010
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosisE Ann Yeh, Emmanuelle Waubant, Lauren B Krupp, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 17, 2024
Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosisEllen O'Donnell, Allison Schuette, Michael Waltz, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2019
γδ T Cell-Secreted XCL1 Mediates Anti-CD3-Induced Oral ToleranceRafael M Rezende, Brenda N Nakagaki, Thais G Moreira, et al.The International Journal of Neuroscience|January 20, 2017
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosisGloria Kim, Renxin Chu, Fawad Yousuf, et al.Pageof 41